Lung cancer drug lorlatinib gets extended safety check in ongoing study

NCT ID NCT05144997

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to the drug lorlatinib for people with a specific type of lung cancer (ALK-positive or ROS1-positive non-small cell lung cancer) who are already benefiting from it in earlier Pfizer studies. The main goal is to track long-term safety and side effects. About 76 participants will take the drug and be monitored over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib
What this could lead to: If successful, this study will confirm that long-term lorlatinib use is safe and continues to control ALK/ROS1-positive non-small cell lung cancer.
What could go wrong: This is a small, single-arm continuation study, not a new treatment test. It cannot prove lorlatinib works better than other options, and side effects may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NSCLC

Contacts and locations

Locations

Aichi Cancer Center Hospital

Nagoya, Aichi-ken, 464-8681, Japan
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Beijing Chest Hospital, Capital Medical University

Beijing, Beijing Municipality, 100000, China
Bhaktivedanta Hospital & Research Institute

Thane, Maharashtra, 401107, India
CHU de Rennes - Hôpital Pontchaillou

Rennes, 35033, France
Chao Family Comprehensive Cancer Center and Ambulatory Care

Irvine, California, 92612, United States
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
General Hospital of Eastern Theater Command

Nanjing, Jiangsu, 210002, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China
Healthcare Global Enterprises

Bengaluru, Karnataka, 560027, India
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hunan Provincial Tumor Hospital

Changsha, Hunan, 410013, China
Institut Gustave Roussy

Villejuif, 94805, France
Jilin Cancer Hospital

Changchun, Jilin, 130000, China
National Cancer Centre Singapore

Singapore, 168583, Singapore
National Taiwan University Hospital

Taipei, 10002, Taiwan
National University Hospital

Singapore, 119074, Singapore
Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200030, China
Sichuan Cancer hospital

Chengdu, Sichuan, 610041, China
Sir Run Shaw Hospital

Hangzhou, Qiantang District, 310016, China
The First Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China
The Second Affiliated Hospital of PLA Air Force Medical University

Xi'an, Shaanxi, 710038, China
The Second Affiliated Hospital of Zhejiang University College of Medicine

Hangzhou, Zhejiang, 310052, China
The first hospital of jilin university

Changchun, Jilin, 130021, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.